Ocular Therapeutix (OCUL) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

OCUL Stock Forecast

Ocular Therapeutix stock forecast is as follows: an average price target of $16.00 (represents a 88.24% upside from OCUL’s last price of $8.50) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

OCUL Price Target

The average price target for Ocular Therapeutix (OCUL) is $16.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $17.00 to $15.00. This represents a potential 88.24% upside from OCUL's last price of $8.50.

OCUL Analyst Ratings

Buy

According to 5 Wall Street analysts, Ocular Therapeutix's rating consensus is 'Buy'. The analyst rating breakdown for OCUL stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Ocular Therapeutix Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 08, 2024	Colleen Kusy	Robert W. Baird	$17.00	$8.37	103.11%	100.00%
Jun 27, 2024	Biren Amin	Piper Sandler	$15.00	$6.71	123.55%	76.47%
Jun 14, 2024	Yi Chen	H.C. Wainwright	$14.00	$5.89	137.77%	64.71%
Mar 12, 2024	Jonathan Wolleben	JMP Securities	$24.00	$9.29	158.34%	182.35%
Jun 07, 2022	Joseph Catanzaro	Piper Sandler	$10.00	$3.78	164.55%	17.65%

The latest Ocular Therapeutix stock forecast, released on Aug 08, 2024 by Colleen Kusy from Robert W. Baird, set a price target of $17.00, which represents a 103.11% increase from the stock price at the time of the forecast ($8.37), and a 100.00% increase from OCUL last price ($8.50).

Ocular Therapeutix Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$17.50
Last Closing Price	$8.50	$8.50	$8.50
Upside/Downside	-100.00%	-100.00%	105.88%

In the current month, the average price target of Ocular Therapeutix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ocular Therapeutix's last price of $8.50. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 16, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 19, 2024	Piper Sandler	Overweight	Overweight	Hold
Aug 01, 2024	Sandler O'Neill	Market Outperform	Market Outperform	Hold
Aug 01, 2024	Sandler O'Neil	Underperform	Underperform	Hold
Jun 27, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 20, 2024	Cowen & Co.	Hold	Buy	Upgrade
Jun 14, 2024	H.C. Wainwright	Underperform	Underperform	Hold
Jun 14, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Jun 14, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 14, 2024	Cowen & Co.	Hold	Hold	Hold
May 08, 2024	Cowen & Co.	Hold	Hold	Hold
Apr 16, 2024	JMP Securities	Underperform	Underperform	Hold
Apr 16, 2024	Piper Sandler	Market Outperform	Market Outperform	Hold
Mar 13, 2024	Piper Sandler	Market Perform	Market Perform	Hold
Mar 13, 2024	JMP Securities	Underperform	Underperform	Hold
Mar 12, 2024	Cowen & Co.	Market Perform	Market Perform	Hold
Mar 12, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Feb 26, 2024	Piper Sandler	Overweight	Overweight	Hold
Jun 07, 2022	Piper Sandler	Overweight	Overweight	Hold

Ocular Therapeutix's last stock rating was published by H.C. Wainwright on Oct 16, 2024. The company gave OCUL a "Buy" rating, the same as its previous rate.

Ocular Therapeutix Financial Forecast

Ocular Therapeutix Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$14.80M	$14.95M	$15.03M	$13.37M	$14.08M	$11.96M	$12.27M	$13.19M	$12.31M	$12.15M	$11.72M	$7.34M	$7.35M	$5.88M	$1.57M	$2.61M	$2.26M	$829.00K
Avg Forecast	$17.50M	$17.40M	$17.10M	$16.90M	$17.45M	$17.33M	$17.41M	$16.79M	$17.21M	$17.13M	$15.85M	$15.36M	$15.70M	$15.23M	$14.62M	$14.09M	$13.53M	$14.27M	$14.25M	$13.96M	$13.94M	$12.45M	$10.82M	$7.64M	$7.73M	$5.50M	$1.50M	$2.66M	$2.19M	$580.00K
High Forecast	$18.34M	$18.24M	$17.92M	$17.71M	$18.29M	$18.17M	$18.25M	$17.56M	$20.62M	$17.13M	$15.85M	$15.36M	$16.11M	$15.96M	$15.33M	$14.77M	$14.18M	$14.27M	$14.25M	$13.96M	$13.94M	$12.45M	$10.82M	$7.64M	$7.73M	$5.50M	$1.50M	$2.66M	$2.19M	$580.00K
Low Forecast	$16.54M	$16.44M	$16.16M	$15.97M	$16.49M	$16.38M	$16.46M	$16.00M	$15.13M	$17.13M	$15.85M	$15.36M	$15.09M	$14.39M	$13.82M	$13.32M	$12.79M	$14.27M	$14.25M	$13.96M	$13.94M	$12.45M	$10.82M	$7.64M	$7.73M	$5.50M	$1.50M	$2.66M	$2.19M	$580.00K
# Analysts	2	2	2	2	1	1	1	4	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	6	4	4	7	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.94%	0.98%	1.03%	0.95%	1.04%	0.84%	0.86%	0.94%	0.88%	0.98%	1.08%	0.96%	0.95%	1.07%	1.05%	0.98%	1.03%	1.43%

Ocular Therapeutix's average Quarter revenue forecast for Mar 24 based on 4 analysts is $15.36M, with a low forecast of $15.36M, and a high forecast of $15.36M. OCUL's average Quarter revenue forecast represents a 3.79% increase compared to the company's last Quarter revenue of $14.80M (Dec 23).

Ocular Therapeutix EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	6	4	4	7	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-19.09M	$-19.21M	$-20.57M	$-21.99M	$-18.94M	$-20.75M	$-19.29M	$-17.26M	$-18.04M	$4.91M	$-6.21M	$5.45M	$-83.22M	$-9.56M	$-34.17M	$-19.14M	$-23.54M	$-16.46M
Avg Forecast	$-17.50M	$-17.40M	$-17.10M	$-16.90M	$-17.45M	$-17.33M	$-17.41M	$-16.79M	$-17.21M	$-17.13M	$-15.85M	$-17.26M	$-15.70M	$-15.23M	$-14.62M	$-15.69M	$-26.37M	$-14.27M	$-14.25M	$-14.26M	$-13.94M	$-12.45M	$-10.82M	$-7.64M	$-7.73M	$-5.50M	$-1.50M	$-17.08M	$-2.19M	$-580.00K
High Forecast	$-16.54M	$-16.44M	$-16.16M	$-15.97M	$-16.49M	$-16.38M	$-16.46M	$-16.00M	$-15.13M	$-17.13M	$-15.85M	$-13.81M	$-15.09M	$-14.39M	$-13.82M	$-12.55M	$-21.10M	$-14.27M	$-14.25M	$-11.41M	$-13.94M	$-12.45M	$-10.82M	$-7.64M	$-7.73M	$-5.50M	$-1.50M	$-13.66M	$-2.19M	$-580.00K
Low Forecast	$-18.34M	$-18.24M	$-17.92M	$-17.71M	$-18.29M	$-18.17M	$-18.25M	$-17.56M	$-20.62M	$-17.13M	$-15.85M	$-20.71M	$-16.11M	$-15.96M	$-15.33M	$-18.83M	$-31.65M	$-14.27M	$-14.25M	$-17.12M	$-13.94M	$-12.45M	$-10.82M	$-7.64M	$-7.73M	$-5.50M	$-1.50M	$-20.49M	$-2.19M	$-580.00K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.22%	1.26%	1.41%	1.40%	0.72%	1.45%	1.35%	1.21%	1.29%	-0.39%	0.57%	-0.71%	10.77%	1.74%	22.80%	1.12%	10.72%	28.38%

4 analysts predict OCUL's average Quarter EBITDA for Dec 21 to be $-13.94M, with a high of $-13.94M and a low of $-13.94M. This is -383.97% lower than Ocular Therapeutix's previous annual EBITDA (Sep 21) of $4.91M.

Ocular Therapeutix Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	6	4	4	7	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-29.22M	$-516.00K	$-20.68M	$-36.40M	$-11.72M	$-26.83M	$-17.62M	$-7.25M	$-5.53M	$2.66M	$-8.48M	$3.12M	$-85.61M	$-11.94M	$-36.57M	$-21.51M	$-26.02M	$-18.78M
Avg Forecast	$-56.78M	$-55.11M	$-55.11M	$-55.11M	$-46.42M	$-45.42M	$-44.75M	$-44.09M	$-41.93M	$-40.53M	$-36.95M	$-21.01M	$-49.47M	$-47.95M	$-50.34M	$-19.10M	$-6.79M	$-39.52M	$-36.81M	$-17.37M	$-38.80M	$-43.11M	$-34.82M	$6.15M	$-27.64M	$-40.13M	$-49.75M	$-19.19M	$-69.65M	$-84.02M
High Forecast	$-52.72M	$-51.17M	$-51.17M	$-51.17M	$-43.11M	$-42.18M	$-41.56M	$-42.32M	$-25.52M	$-37.64M	$-34.31M	$-16.81M	$-31.80M	$-44.53M	$-46.74M	$-15.28M	$-5.44M	$-39.52M	$-36.81M	$-13.89M	$-38.80M	$-43.11M	$-34.82M	$7.38M	$-27.64M	$-40.13M	$-49.75M	$-15.35M	$-69.65M	$-84.02M
Low Forecast	$-60.33M	$-58.55M	$-58.55M	$-58.55M	$-49.33M	$-48.26M	$-47.55M	$-45.85M	$-51.05M	$-43.06M	$-39.26M	$-25.22M	$-95.41M	$-50.95M	$-53.48M	$-22.92M	$-8.15M	$-39.52M	$-36.81M	$-20.84M	$-38.80M	$-43.11M	$-34.82M	$4.92M	$-27.64M	$-40.13M	$-49.75M	$-23.02M	$-69.65M	$-84.02M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.59%	0.01%	0.41%	1.91%	1.73%	0.68%	0.48%	0.42%	0.14%	-0.06%	0.24%	0.51%	3.10%	0.30%	0.74%	1.12%	0.37%	0.22%

Ocular Therapeutix's average Quarter net income forecast for Dec 21 is $-38.80M, with a range of $-38.80M to $-38.80M. OCUL's average Quarter net income forecast represents a -1560.41% decrease compared to the company's last Quarter net income of $2.66M (Sep 21).

Ocular Therapeutix SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	6	4	4	7	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$17.27M	$17.90M	$19.36M	$19.96M	$18.88M	$18.72M	$17.93M	$16.62M	$16.67M	$17.65M	$16.99M	$15.75M	$13.39M	$12.48M	$11.30M	$12.31M	$12.69M	$12.93M
Avg Forecast	$63.30M	$62.94M	$61.86M	$61.13M	$63.13M	$62.70M	$62.99M	$60.74M	$62.26M	$61.96M	$57.33M	$55.57M	$56.80M	$55.09M	$52.90M	$50.98M	$48.96M	$51.62M	$51.54M	$50.49M	$50.43M	$45.05M	$39.16M	$27.62M	$27.96M	$19.90M	$5.42M	$9.61M	$7.94M	$2.10M
High Forecast	$66.35M	$65.97M	$64.83M	$64.07M	$66.17M	$65.71M	$66.02M	$63.53M	$74.60M	$61.97M	$57.33M	$55.57M	$58.29M	$57.74M	$55.45M	$53.43M	$51.31M	$51.62M	$51.54M	$50.49M	$50.43M	$45.05M	$39.16M	$27.62M	$27.96M	$19.90M	$5.42M	$9.61M	$7.94M	$2.10M
Low Forecast	$59.83M	$59.49M	$58.46M	$57.78M	$59.66M	$59.25M	$59.53M	$57.88M	$54.73M	$61.95M	$57.33M	$55.57M	$54.58M	$52.06M	$50.00M	$48.18M	$46.27M	$51.62M	$51.54M	$50.49M	$50.43M	$45.05M	$39.16M	$27.62M	$27.96M	$19.90M	$5.42M	$9.61M	$7.94M	$2.10M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.30%	0.32%	0.37%	0.39%	0.39%	0.36%	0.35%	0.33%	0.33%	0.39%	0.43%	0.57%	0.48%	0.63%	2.08%	1.28%	1.60%	6.16%

Ocular Therapeutix's average Quarter SG&A projection for Mar 24 is $55.57M, based on 4 Wall Street analysts, with a range of $55.57M to $55.57M. The forecast indicates a 221.78% rise compared to OCUL last annual SG&A of $17.27M (Dec 23).

Ocular Therapeutix EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	2	2	2	2	1	1	1	4	6	3	4	4	5	4	4	4	3	3	3	3	4	4	4	4	4	6	4	4	7	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.35	$-0.01	$-0.00	$-0.47	$-0.15	$-0.35	$-0.23	$-0.09	$-0.07	$0.03	$-0.11	$0.04	$-1.21	$-0.19	$-0.64	$-0.41	$-0.53	$-0.40
Avg Forecast	$-0.34	$-0.33	$-0.33	$-0.33	$-0.28	$-0.27	$-0.27	$-0.26	$-0.25	$-0.24	$-0.22	$-0.19	$-0.30	$-0.29	$-0.30	$-0.26	$-0.25	$-0.24	$-0.22	$-0.23	$-0.23	$-0.26	$-0.21	$-0.21	$-0.17	$-0.24	$-0.30	$-0.37	$-0.42	$-0.51
High Forecast	$-0.32	$-0.31	$-0.31	$-0.31	$-0.26	$-0.25	$-0.25	$-0.25	$-0.15	$-0.23	$-0.21	$-0.18	$-0.19	$-0.27	$-0.28	$-0.24	$-0.24	$-0.24	$-0.22	$-0.23	$-0.23	$-0.26	$-0.21	$-0.21	$-0.17	$-0.24	$-0.30	$-0.37	$-0.42	$-0.51
Low Forecast	$-0.36	$-0.35	$-0.35	$-0.35	$-0.30	$-0.29	$-0.28	$-0.27	$-0.31	$-0.26	$-0.24	$-0.20	$-0.57	$-0.31	$-0.32	$-0.28	$-0.27	$-0.24	$-0.22	$-0.23	$-0.23	$-0.26	$-0.21	$-0.21	$-0.17	$-0.24	$-0.30	$-0.37	$-0.42	$-0.51
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.18%	0.03%	0.00%	1.78%	0.59%	1.47%	1.04%	0.40%	0.31%	-0.12%	0.52%	-0.19%	7.26%	0.79%	2.13%	1.11%	1.26%	0.79%

According to 4 Wall Street analysts, Ocular Therapeutix's projected average Quarter EPS for Dec 21 is $-0.23, with a low estimate of $-0.23 and a high estimate of $-0.23. This represents a -880.00% decrease compared to OCUL previous annual EPS of $0.03 (Sep 21).

Ocular Therapeutix Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SPRO	Spero Therapeutics	$1.04	$10.00	861.54%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
CTMX	CytomX Therapeutics	$1.13	$3.47	207.08%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
ASMB	Assembly Biosciences	$14.28	$35.50	148.60%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
ACHL	Achilles Therapeutics	$0.97	$2.00	106.19%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
OCUL	Ocular Therapeutix	$9.02	$16.00	77.38%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy

OCUL Forecast FAQ

Is Ocular Therapeutix a good buy?

Yes, according to 5 Wall Street analysts, Ocular Therapeutix (OCUL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of OCUL's total ratings.

What is OCUL's price target?

Ocular Therapeutix (OCUL) average price target is $16 with a range of $15 to $17, implying a 88.24% from its last price of $8.5. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ocular Therapeutix stock go up soon?

According to Wall Street analysts' prediction for OCUL stock, the company can go up by 88.24% (from the last price of $8.5 to the average price target of $16), up by 100.00% based on the highest stock price target, and up by 76.47% based on the lowest stock price target.

Can Ocular Therapeutix stock reach $13?

OCUL's average twelve months analyst stock price target of $16 supports the claim that Ocular Therapeutix can reach $13 in the near future.

What are Ocular Therapeutix's analysts' financial forecasts?

Ocular Therapeutix's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $68.99M (high $72.27M, low $65.33M), average EBITDA is $-68.988M (high $-65.331M, low $-72.269M), average net income is $-181M (high $-169M, low $-191M), average SG&A $249.56M (high $261.42M, low $236.33M), and average EPS is $-1.082 (high $-1.013, low $-1.144). OCUL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $68.9M (high $72.21M, low $65.12M), average EBITDA is $-68.9M (high $-65.115M, low $-72.214M), average net income is $-222M (high $-206M, low $-236M), average SG&A $249.24M (high $261.23M, low $235.55M), and average EPS is $-1.33 (high $-1.235, low $-1.413).

Did the OCUL's actual financial results beat the analysts' financial forecasts?

Based on Ocular Therapeutix's last annual report (Dec 2023), the company's revenue was $57.87M, which missed the average analysts forecast of $59.65M by -2.98%. Apple's EBITDA was $-82.382M, beating the average prediction of $-61.246M by 34.51%. The company's net income was $-80.736M, missing the average estimation of $-167M by -51.61%. Apple's SG&A was $74.49M, missing the average forecast of $215.77M by -65.48%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.148 by -99.92%. In terms of the last quarterly report (Dec 2023), Ocular Therapeutix's revenue was $14.8M, missing the average analysts' forecast of $15.7M by -5.74%. The company's EBITDA was $-19.091M, beating the average prediction of $-15.703M by 21.58%. Ocular Therapeutix's net income was $-29.22M, missing the average estimation of $-49.472M by -40.94%. The company's SG&A was $17.27M, missing the average forecast of $56.8M by -69.60%. Lastly, the company's EPS was $-0.35, beating the average prediction of $-0.296 by 18.14%